Real	O
role	O
of	O
β-	B:C0001645
blockers	I:C0001645
in	O
regression	O
of	O
left	O
ventricular	I:C0455825
mass	I:C0455825
in	O
hypertension	O
patients	O
:	O
Bayesian	O
network	I:C0026348
meta-analysis	O
.	O

Real	O
role	O
of	O
β-	O
blockers	I:C0001645
in	O
regression	O
of	O
left	B:C0455825
ventricular	I:C0455825
mass	I:C0455825
in	O
hypertension	O
patients	O
:	O
Bayesian	O
network	I:C0026348
meta-analysis	O
.	O

Real	O
role	O
of	O
β-	O
blockers	I:C0001645
in	O
regression	O
of	O
left	O
ventricular	I:C0455825
mass	I:C0455825
in	O
hypertension	B:C0020538
patients	O
:	O
Bayesian	O
network	I:C0026348
meta-analysis	O
.	O

Real	O
role	O
of	O
β-	O
blockers	I:C0001645
in	O
regression	O
of	O
left	O
ventricular	I:C0455825
mass	I:C0455825
in	O
hypertension	O
patients	O
:	O
Bayesian	B:C0026348
network	I:C0026348
meta-analysis	O
.	O

Real	O
role	O
of	O
β-	O
blockers	I:C0001645
in	O
regression	O
of	O
left	O
ventricular	I:C0455825
mass	I:C0455825
in	O
hypertension	O
patients	O
:	O
Bayesian	O
network	I:C0026348
meta-analysis	B:C0920317
.	O

Left	B:C0149721
ventricular	I:C0149721
hypertrophy	I:C0149721
(	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
)	O
is	O
commonly	O
present	O
in	O
patients	O
with	O
hypertension	O
(	O
hypertension	O
)	O
.	O

Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
(	O
Left	B:C0149721
ventricular	I:C0149721
hypertrophy	I:C0149721
)	O
is	O
commonly	O
present	O
in	O
patients	O
with	O
hypertension	O
(	O
hypertension	O
)	O
.	O

Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
(	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
)	O
is	O
commonly	O
present	O
in	O
patients	O
with	O
hypertension	B:C0020538
(	O
hypertension	O
)	O
.	O

Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
(	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
)	O
is	O
commonly	O
present	O
in	O
patients	O
with	O
hypertension	O
(	O
hypertension	B:C0020538
)	O
.	O

According	O
to	O
the	O
expert	B:C1301746
consensus	I:C1301746
document	I:C1301746
from	O
American	O
,	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
(	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
)	O
and	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
(	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
)	O
were	O
recommended	O
as	O
1st	O
-	O
line	O
therapeutic	O
drugs	I:C0013227
.	O

According	O
to	O
the	O
expert	O
consensus	I:C1301746
document	I:C1301746
from	O
American	B:C0596070
,	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
(	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
)	O
and	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
(	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
)	O
were	O
recommended	O
as	O
1st	O
-	O
line	O
therapeutic	O
drugs	I:C0013227
.	O

According	O
to	O
the	O
expert	O
consensus	I:C1301746
document	I:C1301746
from	O
American	O
,	O
angiotensin	B:C0003015
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
(	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
)	O
and	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
(	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
)	O
were	O
recommended	O
as	O
1st	O
-	O
line	O
therapeutic	O
drugs	I:C0013227
.	O

According	O
to	O
the	O
expert	O
consensus	I:C1301746
document	I:C1301746
from	O
American	O
,	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
(	O
angiotensin	B:C0003015
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
)	O
and	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
(	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
)	O
were	O
recommended	O
as	O
1st	O
-	O
line	O
therapeutic	O
drugs	I:C0013227
.	O

According	O
to	O
the	O
expert	O
consensus	I:C1301746
document	I:C1301746
from	O
American	O
,	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
(	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
)	O
and	O
angiotensin	B:C0815017
receptor	I:C0815017
blockers	I:C0815017
(	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
)	O
were	O
recommended	O
as	O
1st	O
-	O
line	O
therapeutic	O
drugs	I:C0013227
.	O

According	O
to	O
the	O
expert	O
consensus	I:C1301746
document	I:C1301746
from	O
American	O
,	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
(	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
)	O
and	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
(	O
angiotensin	B:C0815017
receptor	I:C0815017
blockers	I:C0815017
)	O
were	O
recommended	O
as	O
1st	O
-	O
line	O
therapeutic	O
drugs	I:C0013227
.	O

According	O
to	O
the	O
expert	O
consensus	I:C1301746
document	I:C1301746
from	O
American	O
,	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
(	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
)	O
and	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
(	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
)	O
were	O
recommended	O
as	O
1st	O
-	O
line	O
therapeutic	B:C0013227
drugs	I:C0013227
.	O

However	O
,	O
none	O
noticed	O
the	O
different	O
efficacy	O
between	O
fat	B:C0304516
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
(	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
)	O
and	O
other	O
β-	O
blockers	I:C0001645
on	O
regression	O
of	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
before	O
.	O

However	O
,	O
none	O
noticed	O
the	O
different	O
efficacy	O
between	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
(	O
fat	B:C0304516
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
)	O
and	O
other	O
β-	O
blockers	I:C0001645
on	O
regression	O
of	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
before	O
.	O

However	O
,	O
none	O
noticed	O
the	O
different	O
efficacy	O
between	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
(	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
)	O
and	O
other	O
β-	B:C0001645
blockers	I:C0001645
on	O
regression	O
of	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
before	O
.	O

However	O
,	O
none	O
noticed	O
the	O
different	O
efficacy	O
between	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
(	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
)	O
and	O
other	O
β-	O
blockers	I:C0001645
on	O
regression	O
of	O
Left	B:C0149721
ventricular	I:C0149721
hypertrophy	I:C0149721
before	O
.	O

The	O
aim	O
of	O
this	O
analysis	B:C0920317
was	O
to	O
compare	O
the	O
efficacy	O
of	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
with	O
the	O
other	O
4	O
different	O
classes	O
of	O
antihypertensive	O
drugs	I:C0003364
(	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
,	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
,	O
calcium	O
channel	I:C0006684
blockers	I:C0006684
[	O
calcium	O
channel	I:C0006684
blockers	I:C0006684
]	O
,	O
and	O
diuretics	O
)	O
on	O
regression	O
of	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
.	O

The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
fat	B:C0304516
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
with	O
the	O
other	O
4	O
different	O
classes	O
of	O
antihypertensive	O
drugs	I:C0003364
(	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
,	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
,	O
calcium	O
channel	I:C0006684
blockers	I:C0006684
[	O
calcium	O
channel	I:C0006684
blockers	I:C0006684
]	O
,	O
and	O
diuretics	O
)	O
on	O
regression	O
of	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
.	O

The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
with	O
the	O
other	O
4	O
different	O
classes	O
of	O
antihypertensive	B:C0003364
drugs	I:C0003364
(	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
,	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
,	O
calcium	O
channel	I:C0006684
blockers	I:C0006684
[	O
calcium	O
channel	I:C0006684
blockers	I:C0006684
]	O
,	O
and	O
diuretics	O
)	O
on	O
regression	O
of	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
.	O

The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
with	O
the	O
other	O
4	O
different	O
classes	O
of	O
antihypertensive	O
drugs	I:C0003364
(	O
angiotensin	B:C0003015
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
,	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
,	O
calcium	O
channel	I:C0006684
blockers	I:C0006684
[	O
calcium	O
channel	I:C0006684
blockers	I:C0006684
]	O
,	O
and	O
diuretics	O
)	O
on	O
regression	O
of	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
.	O

The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
with	O
the	O
other	O
4	O
different	O
classes	O
of	O
antihypertensive	O
drugs	I:C0003364
(	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
,	O
angiotensin	B:C0815017
receptor	I:C0815017
blockers	I:C0815017
,	O
calcium	O
channel	I:C0006684
blockers	I:C0006684
[	O
calcium	O
channel	I:C0006684
blockers	I:C0006684
]	O
,	O
and	O
diuretics	O
)	O
on	O
regression	O
of	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
.	O

The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
with	O
the	O
other	O
4	O
different	O
classes	O
of	O
antihypertensive	O
drugs	I:C0003364
(	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
,	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
,	O
calcium	B:C0006684
channel	I:C0006684
blockers	I:C0006684
[	O
calcium	O
channel	I:C0006684
blockers	I:C0006684
]	O
,	O
and	O
diuretics	O
)	O
on	O
regression	O
of	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
.	O

The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
with	O
the	O
other	O
4	O
different	O
classes	O
of	O
antihypertensive	O
drugs	I:C0003364
(	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
,	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
,	O
calcium	O
channel	I:C0006684
blockers	I:C0006684
[	O
calcium	B:C0006684
channel	I:C0006684
blockers	I:C0006684
]	O
,	O
and	O
diuretics	O
)	O
on	O
regression	O
of	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
.	O

The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
with	O
the	O
other	O
4	O
different	O
classes	O
of	O
antihypertensive	O
drugs	I:C0003364
(	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
,	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
,	O
calcium	O
channel	I:C0006684
blockers	I:C0006684
[	O
calcium	O
channel	I:C0006684
blockers	I:C0006684
]	O
,	O
and	O
diuretics	B:C0012798
)	O
on	O
regression	O
of	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
.	O

The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
with	O
the	O
other	O
4	O
different	O
classes	O
of	O
antihypertensive	O
drugs	I:C0003364
(	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
,	O
angiotensin	O
receptor	I:C0815017
blockers	I:C0815017
,	O
calcium	O
channel	I:C0006684
blockers	I:C0006684
[	O
calcium	O
channel	I:C0006684
blockers	I:C0006684
]	O
,	O
and	O
diuretics	O
)	O
on	O
regression	O
of	O
Left	B:C0149721
ventricular	I:C0149721
hypertrophy	I:C0149721
.	O

Relative	O
trials	B:C0008976
were	O
identified	O
in	O
the	O
PubMed	O
,	O
Web	O
of	I:C2349146
Science	I:C2349146
,	O
OVID	O
EBM	I:C0282443
Reviews	I:C0282443
and	O
Cochrane	O
databases	I:C0242356
,	O
and	O
the	O
relevant	O
papers	O
were	O
examined	O
.	O

Relative	O
trials	O
were	O
identified	O
in	O
the	O
PubMed	B:C1138432
,	O
Web	O
of	I:C2349146
Science	I:C2349146
,	O
OVID	O
EBM	I:C0282443
Reviews	I:C0282443
and	O
Cochrane	O
databases	I:C0242356
,	O
and	O
the	O
relevant	O
papers	O
were	O
examined	O
.	O

Relative	O
trials	O
were	O
identified	O
in	O
the	O
PubMed	O
,	O
Web	B:C2349146
of	I:C2349146
Science	I:C2349146
,	O
OVID	O
EBM	I:C0282443
Reviews	I:C0282443
and	O
Cochrane	O
databases	I:C0242356
,	O
and	O
the	O
relevant	O
papers	O
were	O
examined	O
.	O

Relative	O
trials	O
were	O
identified	O
in	O
the	O
PubMed	O
,	O
Web	O
of	I:C2349146
Science	I:C2349146
,	O
OVID	B:C0282443
EBM	I:C0282443
Reviews	I:C0282443
and	O
Cochrane	O
databases	I:C0242356
,	O
and	O
the	O
relevant	O
papers	O
were	O
examined	O
.	O

Relative	O
trials	O
were	O
identified	O
in	O
the	O
PubMed	O
,	O
Web	O
of	I:C2349146
Science	I:C2349146
,	O
OVID	O
EBM	I:C0282443
Reviews	I:C0282443
and	O
Cochrane	B:C0242356
databases	I:C0242356
,	O
and	O
the	O
relevant	O
papers	O
were	O
examined	O
.	O

Relative	O
trials	O
were	O
identified	O
in	O
the	O
PubMed	O
,	O
Web	O
of	I:C2349146
Science	I:C2349146
,	O
OVID	O
EBM	I:C0282443
Reviews	I:C0282443
and	O
Cochrane	O
databases	I:C0242356
,	O
and	O
the	O
relevant	O
papers	B:C1706852
were	O
examined	O
.	O

We	O
performed	O
both	O
traditional	O
and	O
Bayesian	B:C0026348
meta-analysis	O
of	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
(	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
)	O
about	O
the	O
regression	O
of	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
.	O

We	O
performed	O
both	O
traditional	O
and	O
Bayesian	O
meta-analysis	B:C0920317
of	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
(	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
)	O
about	O
the	O
regression	O
of	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
.	O

We	O
performed	O
both	O
traditional	O
and	O
Bayesian	O
meta-analysis	O
of	O
randomized	B:C0206035
controlled	I:C0206035
trials	I:C0206035
(	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
)	O
about	O
the	O
regression	O
of	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
.	O

We	O
performed	O
both	O
traditional	O
and	O
Bayesian	O
meta-analysis	O
of	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
(	O
randomized	B:C0206035
controlled	I:C0206035
trials	I:C0206035
)	O
about	O
the	O
regression	O
of	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
.	O

We	O
performed	O
both	O
traditional	O
and	O
Bayesian	O
meta-analysis	O
of	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
(	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
)	O
about	O
the	O
regression	O
of	O
Left	B:C0149721
ventricular	I:C0149721
hypertrophy	I:C0149721
.	O

Sensitivity	B:C0936012
analysis	I:C0936012
and	O
regression	O
analysis	I:C0034980
were	O
performed	O
to	O
explore	O
possible	O
sources	O
of	O
heterogeneity	O
.	O

Sensitivity	O
analysis	I:C0936012
and	O
regression	B:C0034980
analysis	I:C0034980
were	O
performed	O
to	O
explore	O
possible	O
sources	O
of	O
heterogeneity	O
.	O

Inconsistency	B:C0936012
analysis	I:C0936012
was	O
performed	O
to	O
check	O
whether	O
the	O
analysis	O
of	O
the	O
trials	O
in	O
the	O
network	O
was	O
indeed	O
consistent	O
.	O

Inconsistency	O
analysis	I:C0936012
was	O
performed	O
to	O
check	O
whether	O
the	O
analysis	B:C0920317
of	O
the	O
trials	O
in	O
the	O
network	O
was	O
indeed	O
consistent	O
.	O

Inconsistency	O
analysis	I:C0936012
was	O
performed	O
to	O
check	O
whether	O
the	O
analysis	O
of	O
the	O
trials	B:C0008976
in	O
the	O
network	O
was	O
indeed	O
consistent	O
.	O

Inconsistency	O
analysis	I:C0936012
was	O
performed	O
to	O
check	O
whether	O
the	O
analysis	O
of	O
the	O
trials	O
in	O
the	O
network	B:C0026348
was	O
indeed	O
consistent	O
.	O

A	O
total	O
of	O
41	O
randomized	B:C0206035
controlled	I:C0206035
trials	I:C0206035
involving	O
2566	O
patients	O
with	O
hypertension	O
and	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
were	O
included	O
in	O
this	O
analysis	O
.	O

A	O
total	O
of	O
41	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
involving	O
2566	O
patients	O
with	O
hypertension	B:C0020538
and	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
were	O
included	O
in	O
this	O
analysis	O
.	O

A	O
total	O
of	O
41	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
involving	O
2566	O
patients	O
with	O
hypertension	O
and	O
Left	B:C0149721
ventricular	I:C0149721
hypertrophy	I:C0149721
were	O
included	O
in	O
this	O
analysis	O
.	O

A	O
total	O
of	O
41	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
involving	O
2566	O
patients	O
with	O
hypertension	O
and	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
were	O
included	O
in	O
this	O
analysis	B:C0920317
.	O

Bayesian	B:C0026348
network	I:C0026348
meta-	O
analysis	I:C0920317
indicated	O
no	O
statistically	O
significant	O
differences	O
between	O
these	O
groups	O
:	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
and	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
(	O
MD	O
,	O
-	O
7.09	O
;	O
95	O
%	O
CI	O
,	O
-	O
14.99	O
,	O
1.27	O
)	O
;	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
and	O
ARB	O
(	O
MD	O
,	O
-	O
2.66	O
;	O
95	O
%	O
Cl	O
,	O
-	O
12.02	O
,	O
6.31	O
)	O
.	O

Bayesian	O
network	I:C0026348
meta-	B:C0920317
analysis	I:C0920317
indicated	O
no	O
statistically	O
significant	O
differences	O
between	O
these	O
groups	O
:	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
and	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
(	O
MD	O
,	O
-	O
7.09	O
;	O
95	O
%	O
CI	O
,	O
-	O
14.99	O
,	O
1.27	O
)	O
;	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
and	O
ARB	O
(	O
MD	O
,	O
-	O
2.66	O
;	O
95	O
%	O
Cl	O
,	O
-	O
12.02	O
,	O
6.31	O
)	O
.	O

Bayesian	O
network	I:C0026348
meta-	O
analysis	I:C0920317
indicated	O
no	O
statistically	O
significant	O
differences	O
between	O
these	O
groups	O
:	O
fat	B:C0304516
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
and	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
(	O
MD	O
,	O
-	O
7.09	O
;	O
95	O
%	O
CI	O
,	O
-	O
14.99	O
,	O
1.27	O
)	O
;	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
and	O
ARB	O
(	O
MD	O
,	O
-	O
2.66	O
;	O
95	O
%	O
Cl	O
,	O
-	O
12.02	O
,	O
6.31	O
)	O
.	O

Bayesian	O
network	I:C0026348
meta-	O
analysis	I:C0920317
indicated	O
no	O
statistically	O
significant	O
differences	O
between	O
these	O
groups	O
:	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
and	O
angiotensin	B:C0003015
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
(	O
MD	O
,	O
-	O
7.09	O
;	O
95	O
%	O
CI	O
,	O
-	O
14.99	O
,	O
1.27	O
)	O
;	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
and	O
ARB	O
(	O
MD	O
,	O
-	O
2.66	O
;	O
95	O
%	O
Cl	O
,	O
-	O
12.02	O
,	O
6.31	O
)	O
.	O

Bayesian	O
network	I:C0026348
meta-	O
analysis	I:C0920317
indicated	O
no	O
statistically	O
significant	O
differences	O
between	O
these	O
groups	O
:	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
and	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
(	O
MD	O
,	O
-	O
7.09	O
;	O
95	O
%	O
CI	O
,	O
-	O
14.99	O
,	O
1.27	O
)	O
;	O
fat	B:C0304516
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
and	O
ARB	O
(	O
MD	O
,	O
-	O
2.66	O
;	O
95	O
%	O
Cl	O
,	O
-	O
12.02	O
,	O
6.31	O
)	O
.	O

Bayesian	O
network	I:C0026348
meta-	O
analysis	I:C0920317
indicated	O
no	O
statistically	O
significant	O
differences	O
between	O
these	O
groups	O
:	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
and	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
(	O
MD	O
,	O
-	O
7.09	O
;	O
95	O
%	O
CI	O
,	O
-	O
14.99	O
,	O
1.27	O
)	O
;	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
and	O
ARB	B:C0815017
(	O
MD	O
,	O
-	O
2.66	O
;	O
95	O
%	O
Cl	O
,	O
-	O
12.02	O
,	O
6.31	O
)	O
.	O

Although	O
fat	B:C0304516
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
showed	O
greater	O
efficacy	O
when	O
compared	O
with	O
diuretic	O
(	O
MD	O
,	O
13.04	O
;	O
95	O
%	O
CI	O
,	O
3.38	O
,	O
22.59	O
)	O
or	O
CCB	O
(	O
MD	O
,	O
10.90	O
;	O
95	O
%	O
CI	O
,	O
1.98	O
,	O
19.49	O
)	O
.	O

Although	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
showed	O
greater	O
efficacy	O
when	O
compared	O
with	O
diuretic	B:C0012798
(	O
MD	O
,	O
13.04	O
;	O
95	O
%	O
CI	O
,	O
3.38	O
,	O
22.59	O
)	O
or	O
CCB	O
(	O
MD	O
,	O
10.90	O
;	O
95	O
%	O
CI	O
,	O
1.98	O
,	O
19.49	O
)	O
.	O

Although	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
showed	O
greater	O
efficacy	O
when	O
compared	O
with	O
diuretic	O
(	O
MD	O
,	O
13.04	O
;	O
95	O
%	O
CI	O
,	O
3.38	O
,	O
22.59	O
)	O
or	O
CCB	B:C0006684
(	O
MD	O
,	O
10.90	O
;	O
95	O
%	O
CI	O
,	O
1.98	O
,	O
19.49	O
)	O
.	O

The	O
probabilities	O
of	O
being	O
among	O
the	O
most	O
efficacious	O
treatments	B:C0087111
were	O
:	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
(	O
72	O
%	O
)	O
,	O
ARB	O
(	O
27	O
%	O
)	O
,	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
(	O
0.01	O
%	O
)	O
,	O
CCB	O
(	O
0.00	O
%	O
)	O
,	O
and	O
diuretic	O
(	O
0.00	O
%	O
)	O
.	O

The	O
probabilities	O
of	O
being	O
among	O
the	O
most	O
efficacious	O
treatments	O
were	O
:	O
fat	B:C0304516
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
(	O
72	O
%	O
)	O
,	O
ARB	O
(	O
27	O
%	O
)	O
,	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
(	O
0.01	O
%	O
)	O
,	O
CCB	O
(	O
0.00	O
%	O
)	O
,	O
and	O
diuretic	O
(	O
0.00	O
%	O
)	O
.	O

The	O
probabilities	O
of	O
being	O
among	O
the	O
most	O
efficacious	O
treatments	O
were	O
:	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
(	O
72	O
%	O
)	O
,	O
ARB	B:C0815017
(	O
27	O
%	O
)	O
,	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
(	O
0.01	O
%	O
)	O
,	O
CCB	O
(	O
0.00	O
%	O
)	O
,	O
and	O
diuretic	O
(	O
0.00	O
%	O
)	O
.	O

The	O
probabilities	O
of	O
being	O
among	O
the	O
most	O
efficacious	O
treatments	O
were	O
:	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
(	O
72	O
%	O
)	O
,	O
ARB	O
(	O
27	O
%	O
)	O
,	O
angiotensin	B:C0003015
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
(	O
0.01	O
%	O
)	O
,	O
CCB	O
(	O
0.00	O
%	O
)	O
,	O
and	O
diuretic	O
(	O
0.00	O
%	O
)	O
.	O

The	O
probabilities	O
of	O
being	O
among	O
the	O
most	O
efficacious	O
treatments	O
were	O
:	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
(	O
72	O
%	O
)	O
,	O
ARB	O
(	O
27	O
%	O
)	O
,	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
(	O
0.01	O
%	O
)	O
,	O
CCB	B:C0006684
(	O
0.00	O
%	O
)	O
,	O
and	O
diuretic	O
(	O
0.00	O
%	O
)	O
.	O

The	O
probabilities	O
of	O
being	O
among	O
the	O
most	O
efficacious	O
treatments	O
were	O
:	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
(	O
72	O
%	O
)	O
,	O
ARB	O
(	O
27	O
%	O
)	O
,	O
angiotensin	O
-	I:C0003015
converting	I:C0003015
enzyme	I:C0003015
inhibitor	I:C0003015
(	O
0.01	O
%	O
)	O
,	O
CCB	O
(	O
0.00	O
%	O
)	O
,	O
and	O
diuretic	B:C0012798
(	O
0.00	O
%	O
)	O
.	O

Evidence	O
from	O
our	O
analysis	B:C0920317
reveals	O
that	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
have	O
potential	O
to	O
become	O
1st	O
-	O
line	O
therapeutic	O
drugs	I:C0013227
in	O
hypertension	O
and	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
patients	O
.	O

Evidence	O
from	O
our	O
analysis	O
reveals	O
that	O
fat	B:C0304516
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
have	O
potential	O
to	O
become	O
1st	O
-	O
line	O
therapeutic	O
drugs	I:C0013227
in	O
hypertension	O
and	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
patients	O
.	O

Evidence	O
from	O
our	O
analysis	O
reveals	O
that	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
have	O
potential	O
to	O
become	O
1st	O
-	O
line	O
therapeutic	B:C0013227
drugs	I:C0013227
in	O
hypertension	O
and	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
patients	O
.	O

Evidence	O
from	O
our	O
analysis	O
reveals	O
that	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
have	O
potential	O
to	O
become	O
1st	O
-	O
line	O
therapeutic	O
drugs	I:C0013227
in	O
hypertension	B:C0020538
and	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
patients	O
.	O

Evidence	O
from	O
our	O
analysis	O
reveals	O
that	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
have	O
potential	O
to	O
become	O
1st	O
-	O
line	O
therapeutic	O
drugs	I:C0013227
in	O
hypertension	O
and	O
Left	B:C0149721
ventricular	I:C0149721
hypertrophy	I:C0149721
patients	O
.	O

However	O
,	O
the	O
real	O
efficacy	O
of	O
fat	B:C0304516
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
on	O
regression	O
of	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
should	O
be	O
confirmed	O
by	O
further	O
large	O
,	O
high	O
quality	O
trials	O
considering	O
the	O
limitation	O
of	O
the	O
study	O
number	O
.	O

However	O
,	O
the	O
real	O
efficacy	O
of	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
on	O
regression	O
of	O
Left	B:C0149721
ventricular	I:C0149721
hypertrophy	I:C0149721
should	O
be	O
confirmed	O
by	O
further	O
large	O
,	O
high	O
quality	O
trials	O
considering	O
the	O
limitation	O
of	O
the	O
study	O
number	O
.	O

However	O
,	O
the	O
real	O
efficacy	O
of	O
fat	O
-	I:C0304516
soluble	I:C0304516
and	I:C0304516
selective	I:C0304516
β	I:C0304516
1	I:C0304516
-	I:C0304516
receptor	I:C0304516
blockers	I:C0304516
on	O
regression	O
of	O
Left	O
ventricular	I:C0149721
hypertrophy	I:C0149721
should	O
be	O
confirmed	O
by	O
further	O
large	O
,	O
high	O
quality	O
trials	B:C0008976
considering	O
the	O
limitation	O
of	O
the	O
study	O
number	O
.	O

